PMEF
WHWK

Point72 Middle East FZE’s Whitehawk Therapeutics WHWK Stock Holding History

Point72 Middle East FZE’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-376
Closed -$4.82K – 2297
2022
Q4 		$4.82K Buy
+376
New +$4.91K ﹤0.01% 1780

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Middle East FZE's WHWK Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Whitehawk Therapeutics (WHWK) in Q1 2023, closing a stake of 376 shares — an estimated $4.82K sold.

Point72 Middle East FZE first reported a position in WHWK in Q4 2022 and held it in 1 quarter. The position peaked at $4.82K in Q4 2022. 70 funds tracked by Wall St. Rank hold WHWK as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Whitehawk Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 376 Whitehawk Therapeutics shares in Q1 2023, an estimated $4.82K.
  • Point72 Middle East FZE first reported a position in Whitehawk Therapeutics in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Whitehawk Therapeutics position peaked at $4.82K in Q4 2022.
  • 70 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.